CD20-directed Antibody Interactions

CD20-directed Cytolytic Antibody

Endoglycosidase

Arthritis, Rheumatoid

Extravasation of Diagnostic and Therapeutic Materials

Leukemia, Lymphoid

Granulomatosis with Polyangiitis

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Microscopic Polyangiitis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">RITUXAN HYCELA is a combination of rituximab and hyaluronidase human. Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. Rituximab is produced by mammalian cell (Chinese Hamster Ovary) suspension. </p><p>Recombinant human hyaluronidase is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. It is produced by mammalian (Chinese Hamster Ovary) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). It is a glycosylated single-chain protein with an approximate molecular weight of 61 kD. </p><p>RITUXAN HYCELA (rituximab and hyaluronidase human) injection is a colorless to yellowish, clear to opalescent solution supplied in sterile, preservative-free, single-dose vials for subcutaneous use. </p><p>RITUXAN HYCELA is supplied as 1,400 mg rituximab and 23,400 Units hyaluronidase human per 11.7 mL in single-dose vials or 1,600 mg rituximab and 26,800 Units hyaluronidase human per 13.4 mL in single-dose vials. Each mL of solution contains rituximab (120 mg), hyaluronidase human (2,000 Units), L-histidine (0.53 mg), L-histidine hydrochloride monohydrate (3.47 mg), L-methionine (1.49 mg), polysorbate 80 (0.6 mg), α,α-trehalose dihydrate (79.45 mg), and Water for Injection.</p></section>

Rituxan Hycela

rituximab

hyaluronidase, human recombinant

hyaluronidase / rituximab

11.7 ML hyaluronidase, human recombinant 2000 UNT/ML / rituximab 120 MG/ML Injection

11.7 ML hyaluronidase, human recombinant 2000 UNT/ML / rituximab 120 MG/ML Injection [Rituxan Hycela]

13.4 ML hyaluronidase, human recombinant 2000 UNT/ML / rituximab 120 MG/ML Injection

13.4 ML hyaluronidase, human recombinant 2000 UNT/ML / rituximab 120 MG/ML Injection [Rituxan Hycela]

hyaluronidase

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information 

Medication Guide 

Submit MSL Request 

Reimbursement Information 

Pharmacy List 

How To Order Rituxan Hycela 

Billing & Coding Guide: Chronic Lymphoid Leukemia

Billing & Coding Guide: Diffuse Large B-cell Lymphoma (DLBCL)

Billing & Coding Guide: Follicular Lymphoma (FL)

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Combined Prescriber Service Form and Patient Consent Form

Prescriber Service Form - Online Portal 

Patient Consent Form - English

Patient Consent Form - Spanish

My Patient Solutions - HCP Portal (for managing service requests)

Enroll in Patient Savings Program 

Genentech Patient Assistance Program Application - Prescriber Form 

Other HCP Resources 

About Rituxan Hycela 

Doctor Discussion - Before Treatment 

Doctor Discussion Guide

Patient Brochure 

Patient Resources - Financial

Preparing for Treatment 

Receiving Treatment: FL (Initial Treatment)

Receiving Treatment: FL (Maintenance Treatment)

Receiving Treatment: FL (Relapsed/Refractory)

Receiving Treatment: DLBCL (Initial Treatment)

Receiving Treatment: CLL (Initial Treatment & Relapsed)

Instructions For Use: Follicular Lymphoma (FL)

Instructions For Use: Previously Untreated Diffuse Large B- Cell Lymphoma ( DLBCL)

Instructions For Use: Chronic Lymphocytic Leukemia (CLL)